On April 10, 2026, Sana Biotechnology, Inc. entered a stock purchase agreement with Mayo Clinic to sell 7,507,507 shares at $3.33 each, raising approximately $25 million, with an additional $25 million possible depending on Mayo Clinic's election by August 31, 2026. This agreement supports the development of new products, especially related to genetically modified stem-cell derived islet cell products.